The risk of developing diabetes during antipsychotic drug treatment: A nationwide study among 31,856 patients with schizophrenia
Introduction Antipsychotics (AP) are the primary pharmacological treatment for schizophrenia but increase the risk for diabetes, with recent meta-analyses indicating important differences between specific APs. However, these findings are based on randomized clinical trials, which only include 20% o...
Main Authors: | N. Marker Madsen, O. Köhler-Forsberg, C. Garne Rohde, A. Aalkjær Danielsen, O. Mors |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2023-03-01
|
Series: | European Psychiatry |
Online Access: | https://www.cambridge.org/core/product/identifier/S0924933823003395/type/journal_article |
Similar Items
-
Differential effects of specific antipsychotic drugs on metabolic markers and diabetes: A register-based study on 4,909 patients with schizophrenia
by: M. A. Sørensen, et al.
Published: (2023-03-01) -
Peculiarities of personalized selection of antipsychotic drugs for schizophrenia treatment
by: O.O. Khaustova, et al.
Published: (2024-04-01) -
Efficacy of antipsychotic drugs for schizophrenia - Authors' reply.
by: Leucht, S, et al.
Published: (2013) -
A systematic review of atypical antipsychotic drugs in schizophrenia
by: A-.M. Bagnall, et al.
Published: (2003-01-01) -
The effects of antipsychotic drugs on depression level in patients with schizophrenia: clozapine vs. other atypical antipsychotics
by: Hülya Ertekin, et al.
Published: (2016-08-01)